Category:

Novel Therapeutic

Description:

The present invention relates to a drug molecule structurally related to methylphenidate (Ritalin®, Concerta®, others) resulting from a synthetic substitution of a functional group that results in advantageous aspects for use in the treatment of child, adolescent and adult ADHD and ADHD with comorbid disorders.  Additionally, this novel molecule can likely be used for a variety of other indications including, the excessive daytime sleep associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Shiftwork Sleep Disorder, depression, apathy, and a variety of other fatigue syndromes associated with diseases such as multiple sclerosis (MS) and Parkinson's Disease.  Additionally, the inherent stimulant effects of this novel compound may also be useful as a treatment to counter the problematic sedating side effects from other therapeutic agents used in treating a variety of disorders (i.e. sedating antipsychotic agents used to treat a variety of psychiatric disorders, and sedation associated with high-dose opiate analgesics)

The inventors at the Medical University of South Carolina have generated preliminary data testing relevant doses of the novel compound in animals versus control.  They have also found that unlike methylphenidate, this compound will not result in elevated blood concentrations when mixed with ethanol.  A common problem of abuse for patients prescribed methylphenidate.

Potential Applications:

• Decreased Abuse Potential
• Increased Indications

 

Inventor(s):

Drs. J. Markowitz and K. Patrick

Patent Status:

Availability:

Available for:
exclusive
non-exclusive
licensing.

Technology Status:

Inventors have completed a number of preliminary in vivo animal tox and dosing studies.

Licensing Contact:

Ryan N. Fiorini, MBA, Ph.D.
MUSC Foundation for Research Development
PO Box 250828
Charleston, SC 29425
843.876.1906
fiorinir@musc.edu